Abstract P1-11-26: Impact of pre-operative MammaPrint/BluePrint use for final treatment decisions in patients with Stage II/IIIa HR+/HER2- early-stage breast cancer eligible for neoadjuvant chemotherapy: the DETERMIND study | Publicación